GlassScriptPhysician profile
Alison Arocha
NPI 1497233274
$9,426.82
in general payments reported to CMS, 2019-2025
34 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $854 · 2022: $1,365 · 2023: $2,615 · 2024: $2,855 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,173 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,172.95 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,149.40 | 2021-2025 | |
| Janssen Biotech, INC. | $1,980.15 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,105.16 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $466.50 | 2021-2025 | Omvoh |
| Celgene Corporation | $359.01 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $314.23 | 2023-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $293.40 | 2021-2024 | Dificid |
| Ardelyx, INC. | $284.91 | 2022-2025 | Ibsrela |
| Regeneron Pharmaceuticals, INC. | $226.37 | 2024 | Dupixent |
| Gilead Sciences, INC. | $224.21 | 2021-2023 | |
| Novo Nordisk INC | $221.21 | 2021-2022 | |
| Vivus LLC | $215.86 | 2022-2025 | Pancreaze |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.60 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $117.33 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $116.10 | 2023-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $115.27 | 2022-2025 | Suflave, Sutab |
| Celltrion USA INC. | $111.62 | 2025 | Vegzelma |
| Qol Medical, LLC | $109.82 | 2022-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $108.11 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $98.88 | 2023 | |
| Pfizer INC. | $77.99 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $74.62 | 2023 | Rebyota |
| Organon LLC | $66.02 | 2023-2024 | Renflexis, Hadlima |
| Astrazeneca Pharmaceuticals LP | $65.31 | 2021-2022 | |
| Glaxosmithkline, LLC. | $56.31 | 2021-2022 | |
| Medtronic, INC. | $51.75 | 2025 | Gi Genius |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.57 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $48.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $45.57 | 2021 | |
| Amgen INC. | $34.95 | 2021-2022 | |
| Biocon Biologics INC | $29.52 | 2025 | Yesintek |
| Ultragenyx Pharmaceutical INC. | $21.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.17 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Arocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.